- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 79 publications
- Percutaneous Coronary Intervention , 47 publications
- Purinergic P2Y Receptor Antagonists , 41 publications
- Clopidogrel , 35 publications
Research activity
Active clinical trials
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
128 publications
2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease
Journal of Thrombosis and Thrombolysis
Publisher's site2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics
PubMed • Publisher's site2022
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.
Nature reviews. Cardiology
PubMed • Publisher's site2022
Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions
PubMed • Publisher's site2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis
PubMed • Publisher's site